StockData
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31

Lyell Immunopharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$8.80+0.68 (+8.37%)

Close on Oct 19, 2026

Market cap
$205.60M
P/E (TTM)
–
Dividend yield
–

Community

Notes and questions about Lyell Immunopharma from other investors

No posts about LYEL yet

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.